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Mean persistence (days) was 219.7 for QTP, 200.9 for OLZ,
194.8 for RIS, and 179.2 for typical antipsychotics. Kaplan-
Meier survival curves for the typical antipsychotic group showed
that hazards of therapy modiﬁcation differed within 250 days of
antipsychotic initiation compared with after 250 days of therapy.
Extended Cox regression modeling indicated no signiﬁcant dif-
ferences between antipsychotics in hazards of therapy modiﬁca-
tion within 250 days of initiation. However, patients initiated on
typical antipsychotics were 6.3 times more likely to modify
therapy compared with those initiated on QTP after 250 days of
antipsychotic therapy (p < 0.0001). CONCLUSIONS: Adher-
ence and persistence were similar between atypical antipsychotic
groups. The typical antipsychotic group, however, demonstrated
lower adherence and a greater likelihood of modifying therapy
than the quetiapine cohort.
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OBJECTIVES: To compare annual mental health service utiliza-
tion patterns by level of adherence with antipsychotic medica-
tion in the naturalistic treatment of schizophrenia. METHODS:
Data were drawn from a large prospective naturalistic study of
treatment for patients with schizophrenia in the U.S, conducted
between July 1997 and September 2003. Detailed mental health
resource utilization was systematically abstracted from medical
records and augmented with patients’ self report. Annual 
medication possession ratio (MPR) with any antipsychotic was
calculated, and each participant was categorized into 1 of 3
adherence groups: adherent (MPR >= 80%, N = 1758), partially
adherent (60% ≤ MPR < 80%, N = 36), and non-adherent (MPR
< 60%, N = 216). RESULTS: Adherent participants were least
likely to have any psychiatric hospitalization and emergency
room visits (p < 0.05). Compared to non-adherent, adherent 
participants were also signiﬁcantly more likely to be engaged in
outpatient treatment processes as evident by greater likelihood
of participation in any psychosocial group intervention (p <
0.05) and in any medication management with psychiatrists (p
< 0.05). CONCLUSIONS: Medication adherence levels are asso-
ciated with differential use of psychiatric services. Adherence
appears to be associated with lower risk of hospitalization and
emergency room visits and greater engagement in the outpatient
treatment processes.
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OBJECTIVES: Compare discontinuation patterns across atypi-
cal antipsychotic agents within the ﬁrst year after initiating
therapy among Medicaid patients with schizophrenia.
METHODS: Adult Medicaid recipients diagnosed with schizo-
phrenia and having atypical antipsychotic drug prescription
claims between July 1, 2001 and September 30, 2003 were cat-
egorized into ﬁve groups of initial antipsychotic drug received:
aripiprazole (n = 446); olanzapine (n = 1705); quetiapine (n =
1467); risperidone (n = 1580); and ziprasidone (n = 700). Dis-
continuation was measured using reﬁll patterns, allowing 14-day
gaps between expected reﬁll dates, and compared across starting
drug groups using Chi-Square tests. Multivariate Cox propor-
tional hazards models then explored the simultaneous impact of
age, gender, race, hospitalization in the 6 months prior to initial
therapy, and other concurrent antipsychotic drug use when 
initiating therapy, in addition to being on any one of the ﬁve
mutually exclusive drug groups, on discontinuation. Sensitivity
analysis tested the robustness of results using longer allowable
prescription gaps between reﬁlls, and examining multiple
episodes of atypical antipsychotic use by using different deﬁni-
tions of the index date. RESULTS: Patients starting treatment on
either aripiprazole, risperidone, or ziprasidone were not signiﬁ-
cantly different from olanzapine [HR 1.047, 0.973 and 0.990,
respectively] with respect to discontinuation of therapy. 
Quetiapine was associated with signiﬁcantly higher hazard of
discontinuation [HR 1.130, p = 0.0044] compared to olanzap-
ine. Other covariates associated with signiﬁcantly lower discon-
tinuation rates were being male [HR 0.899, p = 0.0008], older
age [HR 0.997, p = 0.0348] and being on concurrent medication
when initiating therapy [HR 0.225, p < 0.001]. Having previous
hospitalization was associated with signiﬁcantly higher discon-
tinuation rate [HR 1.276, p < 0.001]. These results were robust
across sensitivity analyses. CONCLUSIONS: Patients initiating
on ziprasidone, aripiprazole, risperidone and olanzapine had
similar discontinuation at one year. The higher hazard associated
with quetiapine is consistent with the higher rate of discontinu-
ation observed for quetiapine when compared to olanzapine in
Phase I of the CATIE trial.
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OBJECTIVES: To determine the compliance and persistence to
atypical antipsychotics in the treatment of schizophrenia patients
and associated health care utilization. METHODS: The study
sample was based on NC Medicaid claims database. Patients were
included if they had a diagnosis of schizophrenia (ICD-9 295.XX),
received at least two antipsychotic prescriptions during the period
after index date and were continuously enrolled in NC Medicaid
Program during three month prior and one year post treatment
periods. Medication possession ratio (MPR), persistence and
medication use gap were used as compliance measures. Both
descriptive and multivariate model were conducted. RESULTS:
A total of 450 patients were included. Mean age was 42.3 years.
52.4% were men and 33.1% were blacks. Adherent (0.8 <= PR
<= 0.1), non-adherent (MPR < 0.8) and over-adherent (MPR >
1.1) patients accounted for 34.8%, 45.3%, and 18.9% respec-
tively. Approximately 42.4% of patients had medication use gap,
and the average duration of continuous medication use was 229
days. Adherent patients had fewer hospital admissions and hos-
pital days than nonadherent and overadherent patients (0.57 vs.
1.0 vs. 0.82 admissions; 5.2 vs. 10.0 vs. 5.9 days). Patients with
gaps in medication use had more hospital admissions and hospi-
tal days than those without gaps (1.1 vs. 0.64 admissions; 10.4
vs. 5.3 days). In terms of the risk of hospitalization, nonadher-
ent patients were more likely to be hospitalized than adherent
ones (OD: 1.694, 95% CI: 1.019–2.816). Patients with gaps in
medication use were more likely to be hospitalized (OD: 2.589,
95% CI: 1.633–4.106) and had 11 more hospital days than those
without a gap (p = 0.0275). Patients who stayed on medication
longer were less likely to be admitted to hospitals (OD: 0.998,
95% CI: 0.997–0.999). CONCLUSIONS: The results from this
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study demonstrated that non-adherence to atypical antipsychotics
leads to more hospitalizations and hospital days in the treatment
of schizophrenia.
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OBJECTIVES: To identify which patient baseline characteristics
and which types of early changes in patients’ clinical status are
most predictive of switching antipsychotics in the long-term
treatment of schizophrenia. METHODS: This post-hoc analysis
used data from a randomized, open-label, multi-site, one-year
cost-effectiveness trial of olanzapine, risperidone, and typical
antipsychotics in the treatment of schizophrenia. Study protocol
permitted switching of antipsychotics when clinically warranted.
Baseline characteristics were assessed using standard psychiatric
measures and systematic review of medical records. In addition
to baseline socio-demographics, co-morbid medical and psychi-
atric conditions, body weight, clinical, and functional character-
istics, the prediction model included change scores on clinical
measures (PANSS, ﬁve PANSS factor subscales, Barnes Akathisia
Scale, Simpson Angus Scale) during the ﬁrst two weeks of treat-
ment. Cox proportional hazards model was used to identify the
best predictors of switching from patients’ initial randomized
antipsychotic. RESULTS: About one-third (29.5%, 190/644)
switched antipsychotics before the end of the one-year trial. Five
variables were identiﬁed as best predictors of switching during
the 1-year trial (p < 0.05): absence of antipsychotic use in the
prior year, pre-existing depression, lack of lifetime substance use
disorder, less improvement or worsening following two weeks of
treatment on either clinician-rated akathisia (Barnes Akathisia
Scale), and/or anxiety/depression symptoms (PANSS). A strong
trend was observed for female gender (p = 0.058). CONCLU-
SIONS: Switching of antipsychotics appears to be prevalent in
the naturalistic treatment of schizophrenia, and can be predicted
by a small and distinct set of measures. Interestingly, pre-
existing depressive symptomatology and less improvement or
worsening of anxiety and depressive symptoms following two
weeks of treatment were among the more robust predictors of
future switching of antipsychotics in this one-year study.
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OBJECTIVES: To determine and compare the compliance and
persistence to typical and atypical antipsychotics in the treatment
of schizophrenia patients. METHODS: The study was based on
NC Medicaid claims database. Patients were included if they had
a diagnosis of schizophrenia (ICD-9 295.XX), received at least
two antipsychotic prescriptions during the period after index
date and were continuously enrolled in NC Medicaid Program
during three month prior and one year post treatment periods.
Medication possession ratio (MPR), persistence and medication
use gap were used as compliance measures. Both descriptive and
multivariate model were conducted to determine the difference
in adherence/persistence to antipsychotic medications between
typical and atypical antipsychotic. RESULTS: A total of 919
patients (469 in typical and 450 in atypical) met the selection
criteria for 3-month prior and 12-month after antipsychotic
treatment. There were statistically signiﬁcant differences between
typical and atypical antipsychotics in terms of demographics,
comorbidities, resource utilization in prior period, and adher-
ence. As compared with those in typical groups, patients in atyp-
ical group were signiﬁcantly younger (42.3 vs. 44.4, p = 0.0195),
less blacks (33.1% vs. 58.4%), had more comorbid diseases (2.7
vs. 2.3, p = 0.0025), more hospital visits (0.3 vs. 0.17, p = 0.002)
and greater total costs in prior period ($2703 vs. $2010, p =
0.012). The costs and utilization in prior period indicated that
patients in atypical groups were sicker than those in typical
groups. Patients in atypical group were more adherent to
antipsychotics (35.8% vs. 16.4%, p < 0.0001), less gaps (42.4%
vs. 67%, p < 0.0001), and stayed consistently in medication
longer (229 days vs. 146 days). CONCLUSIONS: The results
from this study indicated that there existed signiﬁcant differences
in terms of demographics, compliance and persistence between
typical and atypical antipsychotics in the treatment of 
schizophrenia.
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OBJECTIVES: To assess the clinical, functional, and economic
ramiﬁcations of switching antipsychotics for any cause during
treatment of schizophrenia. METHODS: We used outpatient
data from a randomized, open-label, one-year cost-effectiveness
trial of olanzapine, risperidone, and typical antipsychotics in the
treatment of schizophrenia. Study protocol permitted switching
of antipsychotics when clinically warranted. Resource utilization
was abstracted from medical records. Treatment outcomes were
assessed with standard psychiatric measures. Changes from pre-
to-post switch were assessed among patients who switched from
randomized antipsychotics. Switchers and non-switchers were
compared on risk for crisis-related events (e.g., hospitalization).
RESULTS: About one-third of the patients (30.2%, 185/612)
were switched from randomized antipsychotics: 14.9% from
olanzapine, 27.9% from risperidone, and 48.5% from typical
antipsychotics. Following antipsychotic switch, switchers expe-
rienced signiﬁcant improvements in symptoms and social rela-
tions (p < 0.001), and numerical cost reductions ($3.72 per day
less, p = 0.320). Compared to non-switchers, switchers were at
signiﬁcantly higher risk for crisis-related events (p = 0.006),
experienced them sooner (p = 0.004), and accrued higher 
crisis-related service costs (p < 0.05). CONCLUSIONS:
Although switching antipsychotics is an effective “rescue”
option, it is costly in personal and economic terms. The optimal
treatment strategy is to begin treatment with the antipsychotic
most likely to lead to effective treatment for each individual
patient.
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OBJECTIVES: To review the literature addressing the economic
consequences of nonadherence in the treatment of schizophre-
nia. This study also seeks to extend the review results to provide
